BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 8251898)

  • 1. Treatment of CML with unrelated donor marrow transplant.
    McGlave P
    Leuk Lymphoma; 1993; 11 Suppl 1():209-11. PubMed ID: 8251898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
    Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
    Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
    Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
    Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.
    Szydlo R; Goldman JM; Klein JP; Gale RP; Ash RC; Bach FH; Bradley BA; Casper JT; Flomenberg N; Gajewski JL; Gluckman E; Henslee-Downey PJ; Hows JM; Jacobsen N; Kolb HJ; Lowenberg B; Masaoka T; Rowlings PA; Sondel PM; van Bekkum DW; van Rood JJ; Vowels MR; Zhang MJ; Horowitz MM
    J Clin Oncol; 1997 May; 15(5):1767-77. PubMed ID: 9164184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes.
    Enright H; Davies S; McGlave P
    Clin Transpl; 1994; ():283-93. PubMed ID: 7547549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
    Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
    Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
    Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.
    Davies SM; DeFor TE; McGlave PB; Miller JS; Verfaillie CM; Wagner JE; Weisdorf DJ
    Am J Med; 2001 Apr; 110(5):339-46. PubMed ID: 11286947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program.
    McGlave P; Bartsch G; Anasetti C; Ash R; Beatty P; Gajewski J; Kernan NA
    Blood; 1993 Jan; 81(2):543-50. PubMed ID: 8422471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases.
    McGlave PB; Beatty P; Ash R; Hows JM
    Blood; 1990 Apr; 75(8):1728-32. PubMed ID: 2328322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience.
    Petersdorf EW; Kollman C; Hurley CK; Dupont B; Nademanee A; Begovich AB; Weisdorf D; McGlave P
    Blood; 2001 Nov; 98(10):2922-9. PubMed ID: 11698272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
    Vela-Ojeda J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; Rosas-Cabral A; Esparza MG; García-Chávez J; García-León LD; González-Llaven J
    Arch Med Res; 2000; 31(2):206-9. PubMed ID: 10880729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
    Phillips GL; Barnett MJ; Brain MC; Chan KW; Huebsch LB; Klingemann HG; Meharchand J; Reece DE; Rybka WB; Shepherd JD
    Bone Marrow Transplant; 1991 Dec; 8(6):477-87. PubMed ID: 1790428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors.
    Anasetti C; Hansen JA
    Transfus Sci; 1994 Sep; 15(3):221-30. PubMed ID: 10155543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
    Gratwohl A; Hermans J; Niederwieser D; Frassoni F; Arcese W; Gahrton G; Bandini G; Carreras E; Vernant JP; Bosi A
    Bone Marrow Transplant; 1993 Nov; 12(5):509-16. PubMed ID: 8298562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.